The IL1B gene encodes interleukin-1 beta (IL-1β)¹¹ interleukin-1 beta (IL-1β)
IL-1β is a master pro-inflammatory cytokine produced primarily by activated macrophages; it triggers NF-κB signaling and coordinates broad inflammatory gene expression, one of the most potent drivers of peritoneal inflammation in the body. In endometriosis, IL-1β plays a central and well-documented pathogenic role: it is elevated in the peritoneal fluid of affected women, secreted at higher levels by peritoneal macrophages, and creates the inflammatory milieu that allows ectopic endometrial tissue to implant, survive, and expand. The rs4848306 variant sits 3,737 base pairs upstream of the IL1B transcription start site (in the promoter region), where it can influence how much IL-1β the body produces in response to inflammatory stimuli — including the monthly retrograde menstruation that seeds the peritoneum with endometrial fragments.

The Mechanism

rs4848306 maps to chromosome 2, position 112,840,530 (GRCh38), within the promoter region of IL1B. The IL1B gene is encoded on the minus strand of chromosome 2; the promoter variant is therefore read in the complement direction, with papers frequently describing this position using the coding-strand notation as IL-1B -3737. The reference allele on the plus strand is G (~61% globally); the alternate allele is A (~39%). Haplotype studies in schizophrenia genetics²² Haplotype studies in schizophrenia genetics
A field that has intensively studied IL1B promoter variants because neuroinflammation is central to psychosis pathophysiology; the same promoter logic applies to peritoneal inflammation in endometriosis establish that the G allele at rs4848306 is part of the haplotype associated with elevated IL1B mRNA expression, while the A allele (coding-strand T) predicts reduced IL1B transcriptional output. This makes rs4848306 a regulatory variant that fine-tunes the amplitude of the IL-1β inflammatory response.

IL-1β in the peritoneal cavity acts at multiple points in endometriosis pathogenesis: it promotes adhesion of ectopic endometrial stromal cells to mesothelial surfaces, stimulates vascular endothelial growth factor (VEGF)³³ vascular endothelial growth factor (VEGF)
VEGF drives the neovascularization that sustains implant growth production to vascularize nascent implants, activates matrix metalloproteinases for tissue invasion, and suppresses natural killer cell cytotoxicity that would otherwise clear ectopic cells. A promoter variant that drives higher IL-1β output — the G allele — would amplify each of these steps during the inflammatory cascade that follows retrograde menstruation.

The Evidence

Elevated IL-1β in the peritoneal environment of women with endometriosis is one of the most replicated findings in the field. Sikora et al. found higher peritoneal fluid IL-1β and elevated macrophage IL-1β secretion in women with endometriosis compared to controls⁴⁴ Sikora et al. found higher peritoneal fluid IL-1β and elevated macrophage IL-1β secretion in women with endometriosis compared to controls
Sikora J, et al. Pro-IL-1β and macrophage IL-1β secretion in endometriosis. Ginekologia Polska, 2016, with pro-IL-1β disproportionately elevated, suggesting increased inflammasome-driven IL-1 processing. A complementary study found that IL-1β and ICE (IL-1β converting enzyme) levels were significantly higher in endometriosis peritoneal fluid⁵⁵ IL-1β and ICE (IL-1β converting enzyme) levels were significantly higher in endometriosis peritoneal fluid
Sikora J, et al. IL-1β, IL-18 and ICE in endometriosis. Ginekologia Polska, 2012, implicating dysregulated cytokine maturation in disease progression.

Akoum et al. documented a specific imbalance between IL-1β and its decoy inhibitory receptor (IL-1R2) in endometriosis peritoneal fluid⁶⁶ Akoum et al. documented a specific imbalance between IL-1β and its decoy inhibitory receptor (IL-1R2) in endometriosis peritoneal fluid
Akoum A, et al. Imbalance between IL-1β and IL-1R2 in endometriosis. Journal of Reproductive Immunology, 2008, most pronounced in infertile patients, linking the defect in local IL-1 control directly to infertility risk. This biochemical finding is complemented by genetic evidence: Mier-Cabrera et al. showed that IL1B variants (the +3954 allele, rs1143634) were enriched in stage IV endometriosis cases compared to controls (OR 2.69)⁷⁷ Mier-Cabrera et al. showed that IL1B variants (the +3954 allele, rs1143634) were enriched in stage IV endometriosis cases compared to controls (OR 2.69)
Mier-Cabrera J, et al. TNF-α, IL-1β and IL1-Ra polymorphisms and endometriosis severity. BMC Women's Health, 2022, supporting IL1B genetic variation as a modifier of disease severity rather than merely a bystander.

For rs4848306 specifically, the direct endometriosis evidence is pathway-based rather than variant-specific: the A allele reduces IL1B promoter activity, and lower IL-1β production capacity would logically dampen the peritoneal inflammatory cascade. This is classified as emerging evidence — the pathway plausibility is strong, but genome-wide significant association data for rs4848306 in endometriosis cohorts is not yet published.

Practical Actions

The G allele at rs4848306 is associated with higher IL-1β promoter activity. In the context of endometriosis, where peritoneal IL-1β excess is a documented and replicated finding, GG homozygotes may carry a heightened inflammatory tone that could favor lesion establishment and progression. Because this is an emerging-evidence variant, actions should focus on monitoring and evidence-based lifestyle factors known to modulate the IL-1β/IL-1Ra balance — specifically, dietary omega-3 fatty acids, which suppress IL-1β production, and awareness of symptoms that suggest active peritoneal inflammation.

Interactions

IL1A rs6542095: The IL-1α cytokine (encoded by IL1A) shares the same receptor as IL-1β and operates in the same peritoneal inflammatory cascade. Women carrying both the IL1A rs6542095-C risk allele (elevated IL-1α susceptibility) and the IL1B rs4848306 GG genotype (elevated IL-1β promoter activity) may experience compounded peritoneal IL-1 signaling — two branches of the same inflammatory pathway simultaneously amplified.

IL1RN rs2234663 (IL1B VNTR): The interleukin-1 receptor antagonist (IL-1Ra) competitively inhibits both IL-1α and IL-1β signaling. The IL1RN intron 2 VNTR (rs2234663, IL-1RN*2 allele) has been associated with lower IL-1Ra production in some tissues. A compounded state of high IL-1β (GG at rs4848306) with low IL-1Ra (IL1RN*2 carrier) would represent maximal unchecked IL-1 signaling in the peritoneal cavity.

IL1B rs1143634 (+3954): This IL1B exon 5 synonymous variant is the most studied IL1B variant in endometriosis; the *2 allele was associated with OR 2.69 for stage IV endometriosis in the Mier-Cabrera 2022 cohort. The two variants tag different haplotypes within the IL1B locus and may independently contribute to IL-1β expression amplitude.

Endothelin-1 (ET-1) is one of the most potent vasoconstrictors in human physiology, acting through two receptor subtypes to control vascular tone, blood pressure, and cardiac remodeling. The endothelin receptor type A¹¹ endothelin receptor type A
EDNRA is a G protein-coupled receptor that mediates ET-1's vasoconstriction, smooth muscle proliferation, and aldosterone release effects binds ET-1 with high affinity on vascular smooth muscle cells, arterial walls, and cardiac tissue, triggering sustained vasoconstriction. The rs5335 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The 3'UTR is the section of mRNA after the protein coding sequence; it contains regulatory elements that govern mRNA stability, translation efficiency, and response to microRNAs of EDNRA, where it can influence how much receptor protein is produced without altering the receptor's amino acid sequence.

The Mechanism

The rs5335 G>C change at chromosome 4:147,542,688 (GRCh38) falls within the 3'UTR of the EDNRA gene transcript. Variants in this regulatory region can alter the binding affinity of microRNAs and RNA-binding proteins, changing the stability and translation efficiency of EDNRA mRNA. Evidence from Darrah et al. 2010³³ Darrah et al. 2010
EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severity. Physiological Genomics. 2010 demonstrated that EDNRA polymorphisms, including rs5335, directly associate with EDNRA mRNA levels in smooth muscle cells and with differences in smooth muscle cell proliferation rates — establishing a direct molecular mechanism by which this 3'UTR variant influences vascular biology.

Higher EDNRA receptor expression on vascular smooth muscle cells increases sensitivity to circulating ET-1. Since ET-1 signaling through EDNRA drives sustained vasoconstriction and promotes vascular smooth muscle hypertrophy, genetically elevated EDNRA expression translates to higher vascular resistance and blood pressure. This mechanism is consistent with the clinical observations linking GG genotype to elevated diastolic blood pressure.

The Evidence

The foundational cardiovascular study for rs5335 was Rahman et al. 2008⁴⁴ Rahman et al. 2008
Common genetic variation in the type A endothelin-1 receptor is associated with ambulatory blood pressure: a family study. Journal of Human Hypertension. 2008, which established that naturally occurring genetic variation in EDNRA is associated with ambulatory blood pressure measurements in a family cohort — a study design that controls for shared environmental influences.

More directly, Zeng et al. 2019⁵⁵ Zeng et al. 2019
Associations of EDNRA and EDNRB Polymorphisms with Intracerebral Hemorrhage. World Neurosurgery. 2019 found that GG genotype carriers had significantly higher diastolic blood pressure than CG or CC carriers in intracerebral hemorrhage patients (91.69 vs 84.71 mmHg, p=0.004). This 7 mmHg difference in diastolic pressure is clinically meaningful — chronic diastolic hypertension is a major modifiable risk factor for stroke, heart failure, and renal disease.

Downstream cardiovascular consequences have been documented in multiple outcome studies. Ellis et al. 2012⁶⁶ Ellis et al. 2012
Association between endothelin type A receptor haplotypes and mortality in coronary heart disease. Personalized Medicine. 2012 found EDNRA haplotypes involving rs5335 associated with mortality differences in coronary heart disease patients. Zhang and Sui 2014⁷⁷ Zhang and Sui 2014
Effect of SNP polymorphisms of EDN1, EDNRA, and EDNRB gene on ischemic stroke. Cell Biochemistry and Biophysics. 2014 extended the association to ischemic stroke risk. Griessenauer et al. 2018⁸⁸ Griessenauer et al. 2018
Associations between endothelin polymorphisms and aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery. 2018 linked EDNRA variants to aneurysmal subarachnoid hemorrhage outcomes, vasospasm, and delayed cerebral ischemia — conditions where ET-1-mediated vasoconstriction plays a central pathological role.

In oncology pharmacogenomics, Kopeva et al. 2022⁹⁹ Kopeva et al. 2022
Anthracycline-induced cardiotoxicity in women without cardiovascular diseases. Acta Cardiologica. 2022 identified rs5335 as a molecular predictor of cardiotoxicity from anthracycline chemotherapy (drugs like doxorubicin), suggesting that EDNRA genotype influences how the heart responds to chemotherapy-induced endothelial stress.

Practical Implications

Your rs5335 genotype relates to how sensitively your vasculature responds to endothelin-1 signaling. GG homozygotes — who show elevated EDNRA expression and higher diastolic BP — benefit from earlier and more targeted blood pressure monitoring, particularly diastolic pressure tracking, and benefit more from interventions that modulate the endothelin pathway. Endothelin receptor antagonists (bosentan, ambrisentan, macitentan) are approved drugs for pulmonary arterial hypertension that directly target EDNRA; your genotype may influence response to these agents.

Dietary nitrates (beetroot juice, leafy greens) and supplemental L-arginine support nitric oxide production in endothelial cells, partially counterbalancing ET-1-driven vasoconstriction. Magnesium is a natural calcium antagonist that reduces vascular smooth muscle responsiveness to vasoconstrictors including ET-1. Regular aerobic exercise downregulates endothelin sensitivity over time through shear-stress-mediated increases in eNOS expression.

Interactions

The endothelin signaling system involves both EDNRA and EDNRB receptors, which have opposing vascular effects: EDNRA drives vasoconstriction while EDNRB on endothelial cells promotes vasodilation via nitric oxide. The Zeng 2019 study examined both rs5335 (EDNRA) and EDNRB polymorphisms together. Variants in EDN1 (rs5370, Lys198Asn) affect circulating ET-1 levels and would interact with EDNRA receptor sensitivity variants — individuals with both elevated ET-1 production (EDN1 Lys198Asn) and increased EDNRA receptor sensitivity (rs5335 GG) may face compounded vasoconstriction drive.

The EDNRA rs5335 G allele also shows strong population stratification: it is common in Europeans (~60%) but rare in Africans (~27%), meaning population-specific haplotype contexts may modulate the blood pressure effect direction and magnitude.

Von Willebrand factor is the primary bridge between a damaged blood vessel wall and the platelet plug that stops bleeding. It circulates as a series of multimers of varying size; the largest, high-molecular-weight (HMW) multimers are the most haemostatically active because they unfurl under shear stress to capture platelets at injury sites. Size is regulated by ADAMTS13¹¹ ADAMTS13
A metalloprotease that cleaves VWF at the Tyr1605-Met1606 bond in the A2 domain, converting ultra-large multimers into smaller circulating forms. The rs61750579 variant encodes the Val1607Asp substitution²² Val1607Asp substitution
valine-to-aspartate change at position 1607, immediately C-terminal to the ADAMTS13 scissile bond — one of the most mechanistically direct causes of type 2A von Willebrand disease (VWD) identified to date.

The Mechanism

The A2 domain of VWF normally folds so that the Tyr1605-Met1606 scissile bond is buried and inaccessible to ADAMTS13 in the absence of mechanical force. When large shear stress stretches VWF at sites of high flow, the A2 domain transiently unfurls, exposing the cleavage site for regulated proteolysis. The Val1607Asp substitution introduces a charged aspartate residue immediately adjacent to this bond, destabilising the folded A2 domain and promoting a constitutively open conformation³³ destabilising the folded A2 domain and promoting a constitutively open conformation
structural studies using FRET constructs showed that most type 2A mutations — including those at the cleavage site — separate the domain's N and C termini without requiring applied force. The result is that ADAMTS13 can cleave VWF continuously, even without mechanical provocation. HMW multimers are selectively degraded, leaving only small multimers in circulation that are unable to support effective platelet adhesion under physiological shear conditions.

Hassenpflug et al. expressed all 13 known A2 domain VWD type 2A mutations in recombinant form⁴⁴ Hassenpflug et al. expressed all 13 known A2 domain VWD type 2A mutations in recombinant form
using a standardised proteolysis assay with ADAMTS13 at physiological concentrations and found that 11 of 13 mutants showed increased susceptibility to cleavage compared to wild-type VWF — a finding that mirrors the selective HMW multimer loss seen in patients' plasma. V1607D was among the mutations that increased proteolytic susceptibility. The biochemical outcome — accelerated cleavage — exactly accounts for the absent HMW multimers that define VWD type 2A on gel electrophoresis.

The Evidence

Type 2A VWD caused by the Val1607Asp variant is classified as pathogenic in ClinVar (VCV000000286)⁵⁵ pathogenic in ClinVar (VCV000000286)
Three independent submitters, with classification criteria provided; OMIM allelic variant 613160.0003. ClinVar records document the selective loss of HMW VWF multimers in individuals carrying this variant, consistent with ADAMTS13 hyperactivity at the mutant A2 domain.

Structural modelling by Pozzi et al.⁶⁶ Pozzi et al.
2012, Biophysical Chemistry showed that the Val1607Asp mutation — in contrast to oxidative modifications at the nearby Met1606 residue that impair cleavage — shifts the VWF-ADAMTS13 interaction toward accelerated proteolysis, producing a net haemorrhagic phenotype. The model correctly predicts the clinical observation that these patients bleed rather than clot.

Inheritance is autosomal dominant⁷⁷ autosomal dominant
one mutant allele is sufficient to produce disease, because VWF multimers assembled from a mixture of wild-type and mutant subunits are still hypersusceptible to ADAMTS13 if even one Val1607Asp subunit is incorporated. This distinguishes type 2A VWD from the recessive type 3 VWD — heterozygous carriers of V1607D have full clinical disease, not a silent carrier state.

Practical Actions

Diagnosis of VWD type 2A requires a panel of laboratory tests: VWF antigen (VWF:Ag), VWF ristocetin cofactor activity (VWF:RCo or VWF:GPIbR), factor VIII coagulant activity (FVIII:C), and VWF multimer analysis. The hallmark is a discordant VWF:RCo to VWF:Ag ratio below 0.6 (more activity loss than antigen loss), with absent HMW multimers on gel electrophoresis.

Desmopressin (DDAVP) releases stored VWF from endothelial Weibel-Palade bodies but is only partially effective in type 2A VWD. Atiq et al. found that only ~31% of type 2 VWD patients achieve complete desmopressin response⁸⁸ Atiq et al. found that only ~31% of type 2 VWD patients achieve complete desmopressin response
compared to 100% of type 1 VWD patients without VWF gene variants, and response is highly variant-dependent. For the V1607D mutation — where accelerated proteolysis rapidly degrades the released VWF — the haemostatic benefit from DDAVP is typically short-lived and incomplete. A formal DDAVP trial under clinical supervision is required to determine individual response before relying on it for procedures.

For bleeds and surgical prophylaxis where desmopressin is insufficient, plasma-derived or recombinant VWF concentrate (Vonvendi, Wilate, Humate-P) restores all multimer sizes and is the established treatment. Antifibrinolytic agents (tranexamic acid) are effective adjuncts for mucosal bleeding.

Interactions

ABO blood group independently modulates circulating VWF levels — blood group O reduces VWF by approximately 25% through increased ADAMTS13-mediated clearance. Carriers of V1607D who also have blood group O (tagged by rs505922) may have compounded VWF deficiency beyond what the genotype alone predicts.

The rs1800380 variant (VWF p.Arg854Gln, type 2N VWD) affects the factor VIII binding domain of VWF rather than the A2 domain; compound heterozygotes carrying both V1607D and R854Q would have combined quantitative, qualitative, and FVIII-transport defects, requiring specialist assessment. Other VWF A2 domain variants (rs61750630 and related exon 28 mutations) can co-occur in the same gene and produce compound phenotypes.

Deep inside the MHC class III region on chromosome 6 sits a single letter change that quietly alters how aggressively your immune system attacks your own tissues. CFB R32Q (rs641153) replaces an arginine with a glutamine at position 32 of complement factor B — a serine protease that is the lynchpin of the alternative complement pathway¹¹ alternative complement pathway
The alternative pathway runs continuously at low level, sampling surfaces for pathogens and damaged cells; unlike the classical pathway it requires no antibodies to activate. The result is a version of factor B that is less efficient at amplifying complement activation, reducing inflammatory damage in tissues exposed to chronic complement fire — most critically, the ageing retina.

The Mechanism

Factor B circulates as a zymogen. When it encounters C3b²² C3b
C3b is deposited on surfaces after complement activation and serves as an anchor; CFB binds C3b to form the proenzyme C3bB before cleavage by factor D, it binds and is cleaved by factor D into Ba (released) and Bb. The Bb fragment stays bound to C3b, forming the alternative pathway C3 convertase (C3bBb), which in turn cleaves many more C3 molecules in a powerful amplification loop. The Arg-32 residue sits in the Ba fragment at the C3b binding interface.

The Gln-32 substitution (the A allele, Q variant) reduces CFB's affinity for C3b by approximately fourfold compared with the common Arg-32 form. This means the proenzyme C3bB complex forms less readily, the C3 convertase assembles less efficiently, and the amplification loop runs at lower intensity. The consequence is a measurable dampening of alternative pathway activity — not an abolition (which would cause serious immunodeficiency) but a calibration that reduces bystander tissue damage when the pathway fires in settings like the ageing retinal pigment epithelium.

The Evidence

The R32Q protective association with AMD is one of the most robustly replicated findings in ocular genetics. Gold et al. (Nature Genetics, 2006)³³ Gold et al. (Nature Genetics, 2006)
Screened ~900 AMD cases and ~400 matched controls; identified the H7 haplotype first defined the H7 haplotype — a chromosomal block combining the C2 intron 10 variant (rs547154) and CFB R32Q (rs641153) — which reduced AMD risk with OR 0.45 (95% CI 0.33–0.61). This haplotype arises because the two variants are in very strong linkage disequilibrium (r² ≈ 0.92–0.96), meaning they are almost always inherited together.

Grassmann et al. (2011)⁴⁴ Grassmann et al. (2011)
Case-control study of 367 neovascular AMD cases and 251 controls with subsequent meta-analysis provided the mechanistic confirmation and largest effect size: meta-analysis across 2,600 individuals showed per-allele OR of 0.30 (p = 1.8 × 10⁻³¹) — one of the most statistically significant protective effects ever observed in a complex disease. The in vitro biochemistry confirmed fourfold reduced C3b affinity for the 32Q protein.

A meta-analysis of 15 published studies (Wang et al., 2013)⁵⁵ meta-analysis of 15 published studies (Wang et al., 2013) showed consistent protection across ethnicity: homozygous AA vs GG yielded OR 0.26 (95% CI 0.15–0.45); the dominant model (any A allele vs GG) yielded OR 0.49 (95% CI 0.40–0.59). Protection was observed in both Caucasians and Asians. The A allele is also associated with reduced risk of polypoidal choroidal vasculopathy, an AMD subtype common in Asian populations.

Beyond AMD, the alternative complement pathway's role in autoimmune tissue damage has led researchers to examine CFB variants in systemic lupus erythematosus (SLE). The 6p21 region harbours multiple SLE susceptibility signals, and reduced complement activation (as produced by R32Q) is biologically consistent with lower autoimmune inflammation; the companion intronic CFB variant rs1270942 shows strong SLE risk association (OR ~2.5), with the R32Q protective allele pointing in the opposite direction.

Practical Implications

Carrying the A allele (Gln-32) is a genuine genetic advantage: your alternative complement pathway runs with lower amplification, reducing chronic inflammatory damage to tissues prone to complement-mediated injury. The most clinically validated benefit is AMD protection. While AMD is a polygenic disease and no single variant eliminates risk, having one or two A alleles meaningfully shifts lifetime probability of developing late AMD — particularly the neovascular (wet) form, where complement-driven choroidal neovascularization is a central mechanism.

For the roughly 79% of people who carry only G alleles, AMD risk from this locus is at population baseline. Standard AMD-relevant lifestyle measures — not smoking, lutein-rich diet, UV protection, and regular eye exams after 60 — remain equally important regardless of genotype. The R32Q variant does not confer immunity and interacts with other complement variants (especially CFH Y402H, ARMS2, and C3) to determine individual AMD risk profiles.

Emerging complement inhibitors (including CFB-specific drugs like iptacopan and danicopan) are in advanced clinical trials for AMD and other complement-driven diseases. Interestingly, individuals with R32Q are essentially pharmacogenomic previews of what CFB inhibition achieves — suggesting the same pathway that confers genetic protection may respond particularly well or less well to therapeutic complement blockade, though this has not yet been formally studied.

Interactions

The strongest documented interaction is the H7 haplotype, where CFB R32Q (rs641153) co-occurs with C2 IVS10 (rs547154) in near-complete linkage disequilibrium. Because the two variants are almost always inherited together, the protective effect measured for each individually is largely the same haplotype block acting in concert — with C2 IVS10 reducing classical pathway convertase efficiency and CFB R32Q reducing alternative pathway convertase efficiency.

The protective effect of R32Q is most clinically meaningful when considered alongside CFH Y402H (rs1061170): a person who carries CFH risk alleles (higher AMD risk) and also carries CFB R32Q (lower AMD risk) sits at a partially buffered intermediate. Combined haplotype analyses⁶⁶ Combined haplotype analyses
Gold et al. 2006 showed that C2/CFB haplotypes combined with CFH variants predicted clinical outcome in 74% of AMD cases and 56% of controls. Similarly, C3 R102G (rs2230199) and ARMS2 A69S (rs10490924) add independent risk layers that interact with the complement inhibitory effect of R32Q.

The SLC2A9 gene encodes GLUT9¹¹ GLUT9
Glucose Transporter 9 — despite its name, GLUT9 transports urate 45–60 times faster than glucose in the kidney proximal tubule; it is the dominant transporter for urate reabsorption back into the bloodstream, the largest known genetic determinant of serum uric acid levels in humans. Genetic variants across the SLC2A9 locus account for more of the variance in serum urate than any other single genomic region — more than dietary purines, more than alcohol, more than body weight alone in population studies.

rs6849729 sits in an intron of SLC2A9 at GRCh38 position chr4:9,957,108, just 70 base pairs from the neighboring intronic variant rs6815001 (9,957,038). The two variants share a nearly identical population frequency profile — strongly suggesting they are in tight [linkage disequilibrium | LD — the tendency for nearby variants to be inherited together, such that knowing one tells you a great deal about the other], and both tag the same regulatory haplotype associated with reduced renal urate excretion. The T allele of rs6849729 and the G allele of rs6815001 travel together on the same chromosome copies in most populations.

The Mechanism

GLUT9 exists in two isoforms. The long form (GLUT9a) sits on the basolateral membrane of proximal tubule cells and reabsorbs urate from the interstitium back into the blood. The short form (GLUT9b) on the apical membrane handles urate secretion into the tubular lumen. The balance between these two activities — how much urate the kidney retains versus releases — determines your steady-state serum uric acid level.

Intronic variants like rs6849729 do not change the amino acid sequence of GLUT9. Their effect is regulatory: they alter transcription factor binding, modify the balance of GLUT9a versus GLUT9b expression, or shift splice-site efficiency. Fine-mapping of the SLC2A9 4p16.1 region²² Fine-mapping of the SLC2A9 4p16.1 region
Wei et al. 2014 — identified five independent marginal effects and three epistatic SNP pairs at SLC2A9, establishing that multiple haplotype blocks in this intronic region independently regulate renal urate clearance has confirmed at least five statistically separable effects in this vicinity, and rs6849729 tags one of these blocks.

The T allele at rs6849729 is most frequent in East Asians (~91%), who have the highest gout prevalence globally, and least frequent in people of African ancestry (~33%), where gout has historically been less prevalent. This population frequency gradient — mirroring the pattern observed across multiple SLC2A9 intronic risk variants — strongly suggests the T allele tags a haplotype associated with reduced net urate clearance.

The Evidence

SLC2A9 as the dominant urate locus: Independent GWAS in 2008 established the SLC2A9 intronic region as the strongest known genetic signal for serum uric acid. Vitart et al.³³ Vitart et al. identified variants in introns 4 and 6 of SLC2A9 explaining 1.7–5.3% of serum urate variance in combined Croatian, UK, and German cohorts. At the same time, Döring et al.⁴⁴ Döring et al. replicated the signal in KORA and confirmed a pronounced sex-specific effect: SLC2A9 intronic variants explain 6% of urate variance in women but only 1.2% in men, with the difference attributed to estrogen's independent uricosuric (urate-excreting) action on the kidney.

Genomic neighbourhood fine-mapping: Wei et al. (2014)⁵⁵ Wei et al. (2014) performed conditional analysis of 4p16.1 and found five independent marginal effects and three epistatic SNP pairs in the SLC2A9 region, together explaining 1.5% more urate variance than the lead SNP alone. rs6849729 is situated within this fine-mapped intronic region and shares a population frequency profile consistent with other risk-haplotype tag SNPs at this locus, but has not been the subject of an independent, published GWAS result to date. The evidence for its specific effect is therefore inferred from locus architecture and LD pattern rather than directly cited.

Sex-specific amplification across all SLC2A9 signals: Dalbeth et al. (2015)⁶⁶ Dalbeth et al. (2015) reviewed SLC2A9 genetic architecture across multiple ethnicities and confirmed that sex-specific amplification — 3.4–8.8% variance explained in women versus 0.5–2.0% in men — is a consistent feature of SLC2A9 intronic variants rather than specific to any single tag SNP. Post-menopausal women, who lose estrogen's independent uricosuric buffering, are the most vulnerable subgroup for any SLC2A9 risk haplotype.

Multiple independent SLC2A9 signals: Chen et al. (2020)⁷⁷ Chen et al. (2020) applied conditional analysis in African-ancestry cohorts and identified a second independent signal at SLC2A9 reaching p = 5.75 × 10⁻¹⁷ after conditioning on the primary variant, confirming that the SLC2A9 locus contains multiple causal or tagging variants acting through separable mechanisms. rs6849729, located in the densely tagged intronic region between rs6815001 and rs11942223, is among the candidate tag SNPs for these independent signals.

Practical Actions

Because rs6849729 sits 70 bp from rs6815001 and shares a nearly identical population frequency profile across ancestries, it most likely tags the same regulatory haplotype. T-allele carriers are likely exposed to the same modestly impaired renal urate clearance described for G-allele carriers at rs6815001. The SLC2A9 locus risk is consistently modifiable by diet: reducing dietary purines and fructose lowers the urate load on a transporter that is already working below optimal capacity.

Interactions

rs6849729 and rs6815001: These two intronic variants are 70 bp apart on chr4. Their almost identical ancestry-stratified allele frequencies (European ~42–43% C/T protective, East Asian ~9–11%, African ~67%) strongly indicate tight LD. Their clinical implications are therefore essentially identical; they should be considered redundant signals from the same haplotype block rather than independent compounding risk factors.

rs6849729 and rs3733591 (Arg265His): rs3733591 is a missense variant that directly reduces GLUT9 transport activity. It is statistically independent of the intronic signals in this region. Carrying a risk haplotype at rs6849729 (T allele) in addition to the Arg265His risk allele (C allele at rs3733591) compounds urate elevation from two distinct mechanisms — regulatory (expression/isoform balance) and functional (transport protein efficiency).

rs6849729 and ABCG2 rs2231142: ABCG2 handles intestinal urate secretion rather than renal reabsorption. Risk alleles at ABCG2 and SLC2A9 act through entirely separate pathways and their effects on serum urate are additive. Combined risk across both loci can push serum urate well above 7 mg/dL in otherwise healthy individuals.

Aromatase¹¹ Aromatase
the enzyme encoded by CYP19A1 that converts androgens to estrogens in the final step of estrogen biosynthesis is expressed in the ovaries, adipose tissue, placenta, bone, breast, and brain. It is the only enzyme in vertebrates capable of producing estrogens, making it central to reproductive function, bone metabolism, and hormone balance throughout the lifespan. The rs700519 variant causes a non-synonymous substitution of arginine by cysteine at position 264 of the aromatase protein — a missense change in exon 7. This variant sits in a region of the enzyme with structural significance, and functional studies suggest the Cys264 protein may behave differently from the wild-type Arg264 form, though in vivo evidence across populations is inconsistent.

The Mechanism

The p.Arg264Cys substitution replaces a positively charged arginine residue with a smaller, thiol-bearing cysteine in the substrate-binding region of the aromatase enzyme. Arg264 is thought to contribute to the electrostatic environment of the active site, and its replacement may alter substrate affinity or catalytic efficiency²² Arg264 is thought to contribute to the electrostatic environment of the active site, and its replacement may alter substrate affinity or catalytic efficiency. In an in vitro transfection study using human embryonic kidney 293 cells³³ in vitro transfection study using human embryonic kidney 293 cells
HEK293 cells do not normally express CYP19A1, making this a clean system for comparing allele function, the Cys264 variant protein showed increased conversion of androstenedione to estrogen compared with the wild-type Arg264 form (p<0.001), suggesting enhanced catalytic activity. This directionally supports the hypothesis that Cys264 carriers may have somewhat increased aromatase-mediated estrogen synthesis — but the in vivo effect may be tissue- or context-specific.

Because CYP19A1 is on the minus (coding) strand, papers describing the variant in coding-strand notation call it C>T (C=Arg264, T=Cys264). In genome files (including 23andMe and WGS), alleles appear on the plus strand as G (reference) and A (risk).

The Evidence

The primary study establishing an association between rs700519 and reproductive function is Wang et al. 2011 in Molecular Human Reproduction⁴⁴ Wang et al. 2011 in Molecular Human Reproduction
A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro. Mol Hum Reprod 17:386-391. Genotyping 1,078 participants (PCOS cases and controls), they found the Arg264Cys T allele associated with PCOS risk (uncorrected p=0.004, Bonferroni-corrected p=0.02). The in vitro component showed increased aromatase activity in cells expressing the Cys264 variant (p<0.001 for androstenedione-to-estrogen conversion).

A 2017 Chinese population-based study of 293 PCOS patients undergoing ART found the CC genotype (i.e., wild-type GG on the plus strand) and elevated BMI were associated with unfavorable pregnancy outcomes⁵⁵ the CC genotype (i.e., wild-type GG on the plus strand) and elevated BMI were associated with unfavorable pregnancy outcomes
Dou et al. 2017, Kaohsiung J Med Sci 33:558-566, while the CT+TT genotype group (AG+AA on plus strand) showed higher pregnancy rates. This suggests the Cys264 variant may modulate ovarian response to gonadotropin stimulation in PCOS.

Not all populations show this association. A study of 250 PCOS cases and 250 controls from North India found no significant difference in rs700519 genotype distribution (p=0.635)⁶⁶ A study of 250 PCOS cases and 250 controls from North India found no significant difference in rs700519 genotype distribution (p=0.635)
Kaur et al. 2018, J Assist Reprod Genet, consistent with several South Indian studies. A study of 1,022 elderly Caucasian women found no association between Arg264Cys and circulating estradiol, bone density, or fracture risk⁷⁷ A study of 1,022 elderly Caucasian women found no association between Arg264Cys and circulating estradiol, bone density, or fracture risk
Wang et al. 2011, BMC Med Genet, where the T allele frequency was only 2.4%, limiting power for any AA homozygote analysis.

Beyond reproductive health, a 2007 Shanghai case-control study (1,040 endometrial cancer cases, 1,031 controls) found a multiplicative interaction between rs700519 and BMI among postmenopausal women (p=0.01)⁸⁸ a 2007 Shanghai case-control study (1,040 endometrial cancer cases, 1,031 controls) found a multiplicative interaction between rs700519 and BMI among postmenopausal women (p=0.01)
Tao et al. 2007, Cancer Epidemiol Biomark Prev 16:943-950, with stronger genotype effects in heavier women. A meta-analysis of 9 case-control studies found the rs700519 AA genotype inversely associated with breast cancer risk in dominant and allelic models⁹⁹ meta-analysis of 9 case-control studies found the rs700519 AA genotype inversely associated with breast cancer risk in dominant and allelic models
Lv et al. 2021, Genet Test Mol Biomark (allelic OR 0.84, 95% CI 0.75-0.93). A 2006 Chinese breast cancer cohort found Cys/Cys homozygotes had hazard ratio 2.2 (95% CI 1.2-4.1) for worse disease-free survival¹⁰¹⁰ 2006 Chinese breast cancer cohort found Cys/Cys homozygotes had hazard ratio 2.2 (95% CI 1.2-4.1) for worse disease-free survival
Long et al. 2006, Cancer Epidemiol Biomarkers Prev, though the AA genotype is exceptionally rare in European populations.

Practical Actions

The most relevant implication for women in reproductive years is potential aromatase activity enhancement in the ovaries. If local aromatase activity in granulosa cells is increased in Cys264 carriers, ovarian estrogen synthesis from androgen precursors may be more efficient, contributing to altered estrogen-androgen balance. The ART data further suggest that in women undergoing ovarian stimulation for IVF, genotype may influence gonadotropin response in PCOS. Letrozole, which inhibits aromatase to induce ovulation, is the standard-of-care first-line agent for anovulatory PCOS; carriers with increased baseline aromatase activity may have different dosing requirements, though prospective pharmacogenomics data for rs700519 specifically are limited.

The BMI-interaction finding in endometrial cancer data is a reminder that adipose-derived aromatase is the primary estrogen source postmenopausally, and variants that increase enzyme activity may have amplified effects in the context of excess adipose tissue.

Interactions

Rs700519 and rs700518 are both CYP19A1 coding/functional variants that may influence total aromatase activity through different mechanisms (Cys264 increases catalytic activity; rs700518 Val80 affects expression levels). Women carrying risk genotypes at both loci may have compounded effects on ovarian estrogen synthesis. The clinical direction of that interaction — and whether it matters for fertility outcomes or hormone-sensitive cancer risk — deserves prospective study. See related_snps for other CYP19A1 variants (rs10046, rs4646, rs1062033) that form haplotypes with rs700519.

The cholesterol ester transfer protein (CETP) is a liver-synthesized glycoprotein¹¹ liver-synthesized glycoprotein
CETP facilitates the bidirectional exchange of cholesteryl esters and triglycerides between lipoproteins in plasma that orchestrates cholesterol trafficking between lipoprotein particles. CETP transfers cholesteryl esters from HDL (high-density lipoprotein, the "good" cholesterol) to LDL and VLDL particles, while simultaneously shuttling triglycerides in the opposite direction. The rs708272 variant, known as TaqIB for the restriction enzyme site it creates or disrupts, sits in an intronic region²² intronic region
introns are non-coding sequences within genes that can still affect gene expression through regulatory elements of the CETP gene and modulates both CETP enzyme activity and concentration in plasma. People carrying the B2 allele (the A nucleotide) show 30-40% lower CETP activity, which translates to approximately 10% higher HDL cholesterol levels — yet the cardiovascular benefit of this seemingly favorable lipid shift remains one of genetics' most intriguing puzzles.

The Mechanism

The TaqIB polymorphism doesn't change the CETP protein sequence directly — it's located in intron 1, between coding regions — but it appears to affect gene expression through linkage disequilibrium³³ gene expression through linkage disequilibrium
linkage disequilibrium means this SNP tends to be inherited together with other functional variants in nearby regulatory regions with regulatory elements in the promoter and elsewhere in the gene. The B1 allele (G nucleotide) creates a restriction site for the TaqI enzyme and associates with higher CETP activity, while the B2 allele (A nucleotide) disrupts this site and correlates with reduced enzyme function. Lower CETP activity slows the transfer of cholesteryl esters out of HDL particles, allowing HDL to accumulate more cholesterol. The result: B2 carriers consistently show higher HDL-C concentrations, larger HDL particle sizes, and paradoxically, larger LDL particles as well — a pattern that resembles the lipid profile of people with genetic CETP deficiency⁴⁴ resembles the lipid profile of people with genetic CETP deficiency
complete CETP deficiency from loss-of-function mutations produces extremely high HDL-C (often >100 mg/dL) and has been linked to longevity in some populations, who can have HDL cholesterol levels twice the population average.

The Evidence

The relationship between this variant and cardiovascular disease defies simple categorization. A meta-analysis of 45 studies including over 42,000 participants⁵⁵ meta-analysis of 45 studies including over 42,000 participants
Guo et al. 2016. Associations of Cholesteryl Ester Transfer Protein TaqIB Polymorphism with the Composite Ischemic Cardiovascular Disease Risk and HDL-C Concentrations found that the B2 allele confers protection against ischemic cardiovascular disease in both Asian and Caucasian populations, with the protective effect scaling with allele dose. Yet a comprehensive pooled analysis⁶⁶ comprehensive pooled analysis
Dullaart and Sluiter. 2008. Common variation in the CETP gene and the implications for cardiovascular disease revealed a striking context dependency: in population-based studies of apparently healthy individuals, B2B2 homozygotes actually showed 45% higher cardiovascular risk compared to B1B1 carriers (OR 1.45), despite their elevated HDL. In contrast, among high-risk populations — people selected for existing cardiovascular disease or multiple risk factors — the B2B2 genotype was protective (OR 0.84). This apparent contradiction may reflect survivor bias⁷⁷ survivor bias
high-risk populations have already been selected for disease survival, potentially filtering out B2B2 individuals with poor outcomes or suggest that HDL cholesterol concentration alone doesn't capture HDL function, which may be more important for atheroprotection.

The longevity connection strengthens the case for B2. The landmark Copenhagen City Heart Study⁸⁸ Copenhagen City Heart Study
Barzilai et al. 2021. Following 10,261 participants for up to 34 years followed over 10,000 people for three decades and found that CETP gene polymorphisms reducing enzyme activity — including TaqIB B2 — associated with significantly reduced risk of ischemic heart disease, myocardial infarction, and stroke, plus increased longevity, with no evidence of adverse effects. Meanwhile, a prospective study of 18,245 initially healthy American women⁹⁹ prospective study of 18,245 initially healthy American women
Voight et al. 2010. Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction over 10 years found that each copy of the B2 allele raised HDL-C by 3.1 mg/dL and lowered myocardial infarction risk by 24% (HR 0.76).

Intriguingly, the B2 allele shows a strong gene-diet interaction with alcohol consumption¹⁰¹⁰ strong gene-diet interaction with alcohol consumption
Mehlig et al. 2014. Studying 618 CHD patients. In a study of 618 coronary heart disease patients, B2B2 individuals consuming moderate amounts of alcohol (6.5-13 g ethanol daily for men) had a remarkable 79% reduction in CHD risk (OR 0.21) compared to low drinkers, while B1B1 carriers showed no such benefit. This interaction may reflect alcohol's effects on HDL particle remodeling, which could be amplified when CETP activity is already low.

Practical Implications

If you carry one or two copies of the B2 allele, your HDL cholesterol is likely 5-10% higher than if you carried B1B1, and your LDL and HDL particles tend to be larger and less atherogenic. The cardiovascular implications depend heavily on your broader risk profile. In the absence of other major risk factors, the B2 allele appears modestly protective, particularly if you're a moderate alcohol consumer. However, the variant doesn't eliminate cardiovascular risk — elevated HDL from reduced CETP activity may not confer the same protection as functionally robust HDL achieved through lifestyle. Focus on HDL function rather than HDL concentration¹¹¹¹ HDL function rather than HDL concentration
HDL's anti-inflammatory, antioxidant, and cholesterol efflux capacities matter more than the absolute number: exercise, omega-3 fatty acids, and avoiding oxidative stress all enhance HDL quality independent of CETP genotype.

For those with diabetes, the picture shifts. Several studies suggest the B2 allele's HDL-raising effects are most pronounced in individuals with lower insulin resistance¹²¹² HDL-raising effects are most pronounced in individuals with lower insulin resistance
Bini et al. 2010. Menopause and CETP TaqIB polymorphism effects in type 2 diabetes, BMI, and triglycerides. In type 2 diabetics, B2 carriers with better metabolic control show a more favorable HDL subpopulation profile (larger alpha-1 particles), while those with poor control lose this benefit. If you're B2B2 and managing diabetes or metabolic syndrome, optimizing insulin sensitivity and triglyceride levels may unlock your genotype's protective potential.

The alcohol interaction merits mention but not overinterpretation. While B2B2 individuals appear to derive cardiovascular benefit from light-to-moderate drinking, this doesn't constitute a prescription. Alcohol carries risks beyond cardiovascular disease, and the effect size, while striking, comes from observational data subject to confounding. If you already consume alcohol moderately and are B2B2, the data suggest you may be extracting more cardiovascular benefit than others — but this isn't a reason to start drinking if you don't currently.

Statin therapy appears equally effective across TaqIB genotypes, with no evidence that B1 or B2 status should influence treatment decisions for elevated LDL cholesterol. The variant's effect on HDL is independent of statin-mediated LDL lowering.

Interactions

The TaqIB variant's effects on lipid metabolism position it within a network of related genetic influences. Other CETP polymorphisms, including the promoter variant rs1800775 (-629C>A) and the missense variant rs5882 (I405V), show similar associations with HDL levels and often travel together in haplotype blocks. Compound effects with other HDL metabolism genes — particularly ABCA1, LIPC (hepatic lipase), and APOA1 — could amplify or dampen the TaqIB signal, though few studies have systematically evaluated multi-locus interactions. More broadly, the cardiovascular risk implications of elevated HDL from reduced CETP activity likely depend on LDL levels, triglyceride levels, and inflammatory markers — a reminder that single variants operate within complex, multifactorial disease pathways. Personalized cardiovascular risk assessment should integrate CETP genotype with conventional lipid panels, family history, and metabolic health markers rather than relying on any single genetic signal.

STAT4 (Signal Transducer and Activator of Transcription 4) is a transcription factor at the center of the type I interferon and IL-12 signaling network. When the immune system detects a threat, interferon-alpha and IL-12 bind receptors on T cells¹¹ interferon-alpha and IL-12 bind receptors on T cells
These cytokines activate JAK1/TYK2 and JAK2/TYK2 kinase pairs, which phosphorylate and activate STAT4, triggering STAT4 phosphorylation and nuclear translocation. STAT4 then activates genes driving Th1 differentiation, natural killer cell activation, and IFN-gamma production. The intronic variant rs7574865 in the third intron of STAT4 is the strongest common genetic risk factor for lupus²² strongest common genetic risk factor for lupus
rs7574865 T allele present on 31% of lupus chromosomes vs 22% of control chromosomes; OR 1.55, P=1.87×10⁻⁹ outside the HLA region — a distinction shared with only a handful of loci genome-wide.

The Mechanism

rs7574865 lies deep within intron 3 of STAT4, far from any coding sequence or known splice site. Precisely how it amplifies immune signaling remains under investigation, but the functional consequence is measurable: T allele carriers show significantly higher STAT4 mRNA and protein levels³³ significantly higher STAT4 mRNA and protein levels
Longitudinal study in early arthritis patients: TT genotype showed highest STAT4 protein by western blot; T allele independently associated with mRNA levels after adjusting for disease activity and glucocorticoids than GG homozygotes. The proposed mechanisms include altered transcription factor binding, changes to histone modification sites, or effects on a cryptic regulatory element within the large intron.

Whatever the upstream cause, the downstream effect is amplified. When T allele carriers encounter type I interferons or IL-12, STAT4 signaling is exaggerated⁴⁴ STAT4 signaling is exaggerated
Increased STAT4 expression produces stronger phosphorylation of STAT4 in response to IL-12 and IFN-alpha, amplifying downstream IFN-gamma production, driving excess IFN-gamma production. This dysregulated interferon response is a defining feature of systemic lupus erythematosus: the interferon signature — elevated expression of interferon-stimulated genes — is observed in roughly 75% of SLE patients and correlates with disease severity. STAT4 and IRF5 act additively⁵⁵ STAT4 and IRF5 act additively
Independent effects on SLE susceptibility through separate interferon pathway mechanisms to amplify this interferon dysregulation.

The Evidence

The STAT4 association with autoimmune disease was established in a landmark 2007 NEJM study by Remmers et al.⁶⁶ landmark 2007 NEJM study by Remmers et al.
multiple RA and SLE cohorts; rs7574865 T allele OR 1.32 for RA and OR 1.55 for SLE encompassing thousands of cases and controls. Homozygous TT individuals faced more than a doubled risk for lupus versus GG homozygotes, with a clear dose-response pattern — a genetic hallmark of additive inheritance.

The risk is not uniform across all lupus manifestations. A large phenotyping study⁷⁷ large phenotyping study
1,398 SLE patients sub-classified by ACR criteria; severe nephritis MAF 39.2% vs 22.5% in healthy controls; OR 2.35 for severe nephritis showed the T allele concentrates most strongly in severe nephritis (OR 2.35), anti-dsDNA antibody production (OR 1.86), and early-onset disease. The STAT4 locus also carries cerebrovascular risk: a study of 578 Swedish SLE patients⁸⁸ 578 Swedish SLE patients
Svenungsson et al. 2010; the LD-linked STAT4 variant rs10181656 showed OR 2.3 for ischemic stroke or TIA; risk comparable in magnitude to hypertension; associated with antiphospholipid antibody accumulation found that the LD-linked variant rs10181656 (which tags the same STAT4 risk haplotype) was associated with ischemic cerebrovascular events (OR 2.3), a magnitude comparable to classical vascular risk factors like hypertension. The proposed mechanism involves enhanced antiphospholipid antibody production — pro-thrombotic autoantibodies that promote clotting in blood vessels and the placenta.

Beyond lupus, rs7574865 has been replicated across multiple autoimmune conditions. For rheumatoid arthritis, meta-analyses confirm⁹⁹ meta-analyses confirm
Pooled OR 1.27 across 17 case-control studies (28 comparisons); consistent in European and Asian populations a pooled OR of approximately 1.27. Primary Sjögren's syndrome¹⁰¹⁰ Primary Sjögren's syndrome
124 Caucasian pSS patients vs 1,143 controls; T allele 29.6% in cases vs 22.3% in controls; P=0.01 also shows significant T allele enrichment. The breadth of associations is explained by STAT4's position as a master regulator of Th1 immunity — any condition driven by type I interferons or IL-12 is influenced by STAT4 dosage.

Pharmacogenomic Relevance

Because STAT4 functions downstream of JAK kinases — the very enzymes targeted by tofacitinib, baricitinib, and upadacitinib — the rs7574865 genotype has direct pharmacogenomic implications. A Phase 1 safety trial of tofacitinib in SLE¹¹¹¹ Phase 1 safety trial of tofacitinib in SLE
Double-blind placebo-controlled trial; subjects stratified by STAT4 rs7574865 genotype; T allele carriers showed greater NET complex reduction and more robust T cell activation marker suppression stratified participants by STAT4 genotype and found that T allele carriers showed greater reductions in circulating neutrophil extracellular trap (NET) complexes — a pro-inflammatory substrate elevated in lupus — and more robust suppression of T cell activation markers under tofacitinib treatment. Carriers of the T allele may derive greater benefit from JAK inhibitor therapy precisely because their STAT4-driven interferon amplification is the upstream driver of their disease activity.

Practical Actions

For GT heterozygotes, the ~30-50% elevated risk for SLE warrants awareness of the classic early symptoms — butterfly rash, photosensitivity, symmetric joint pain, serositis, fatigue — and low-threshold referral for antinuclear antibody (ANA) testing if these appear. TT homozygotes carry materially elevated risk for severe lupus nephritis (the STAT4 risk haplotype is also linked to ischemic cerebrovascular events via the LD-tagged variant rs10181656), and benefit from proactive baseline autoantibody testing even before symptoms develop. For patients already diagnosed with SLE or RA who carry the T allele, the JAK inhibitor class (tofacitinib, baricitinib, upadacitinib) directly targets the pathway amplified by this variant and may be particularly effective. Discuss genotype-informed treatment selection with a rheumatologist.

Interactions

The STAT4 rs7574865 T allele and the IRF5 rs10488631 T allele (rs10488631 is a tagging SNP in linkage disequilibrium with the primary IRF5 functional variants) both act within the type I interferon axis but through independent mechanisms. STAT4 amplifies the transcriptional response to interferon signaling; IRF5 amplifies interferon production upstream. Studies confirm their effects on SLE risk are additive rather than synergistic — each additional risk allele at either locus stacks independently onto overall risk. Individuals carrying risk alleles at both STAT4 (rs7574865) and IRF5 (rs10488631) face substantially higher composite SLE risk than either variant alone confers, and this combined burden is the basis for a proposed compound action. The combined recommendation: if you carry both STAT4 rs7574865(T) and IRF5 rs10488631(T) risk alleles, the interferon axis is doubly sensitized — prioritize ANA surveillance, minimize UV light exposure (a known interferon inducer in lupus), and if SLE is diagnosed, present the combined genotype to your rheumatologist as evidence for JAK inhibitor consideration. The companion SNP rs1270942 (CFB) participates in the same lupus genetic architecture through a distinct pathway (alternative complement pathway amplification and immune complex deposition) and can further stratify risk in the setting of renal involvement.

LIN28B encodes an RNA-binding protein that acts as one of the master regulators of developmental timing in humans. Its primary molecular job is to block the maturation of let-7 microRNAs¹¹ let-7 microRNAs
A family of small non-coding RNAs that suppress many growth and developmental genes, which in turn keeps the body in a growth-permissive state. When LIN28B activity declines — a tightly timed developmental switch — let-7 microRNAs rise, suppress growth-promoting signals at the hypothalamic-pituitary axis, and allow the GnRH pulse generator to activate puberty. The rs7759938 variant near LIN28B influences how this switch is timed, advancing or delaying the entire reproductive developmental clock.

This locus has the largest effect size of any common genetic variant associated with age at menarche — larger than any of the other 122 signals identified in a meta-analysis of 182,416 women²² larger than any of the other 122 signals identified in a meta-analysis of 182,416 women
p=1.23×10⁻⁶⁹, Perry et al. 2014.

The Mechanism

rs7759938 sits approximately 26 kb upstream of the LIN28B transcription start site in a regulatory region. The T allele is associated with modestly increased LIN28B expression in relevant tissues, which prolongs the let-7 suppression state beyond what would otherwise occur — paradoxically, higher LIN28B activity means puberty arrives sooner rather than later. The mechanistic pathway runs through the hypothalamic KiSS1/GPR54 axis³³ KiSS1/GPR54 axis
Kisspeptin signaling drives the pulsatile GnRH release that initiates puberty: LIN28B suppresses let-7g, which in turn disinhibits Lin28b target transcripts that stimulate hypothalamic kisspeptin neurons, lowering the threshold for GnRH pulse activation.

The variant is not missense — it does not change the LIN28B protein sequence. Its effect is quantitative and probabilistic rather than deterministic: each T allele shifts the average age at menarche by approximately 5 weeks (around 35 days) earlier, with TT homozygotes averaging roughly 10 weeks earlier menarche than CC homozygotes across European populations.

The Evidence

The original discovery by Perry et al. (2009)⁴⁴ The original discovery by Perry et al. (2009)
Meta-analysis of 17,510 women from 8 cohorts; Nature Genetics 2009 identified rs7759938 as one of the first two common genetic variants ever linked to menarche timing, with p=7×10⁻⁹. Concurrent work by Ong et al. (2009)⁵⁵ Ong et al. (2009)
Nature Genetics; 4,714 index + 16,373 replication subjects confirmed the effect extends to males: the puberty-advancing allele was associated with earlier voice breaking (p=0.006) and earlier pubic hair development (p=0.01), as well as shorter final adult height in both sexes — a consequence of earlier growth plate closure.

Prospective data from Busch et al. (2018)⁶⁶ Busch et al. (2018)
JCEM; 1,478 girls followed longitudinally provided the most granular quantification: each T allele shifted thelarche (breast development) earlier by 0.27 years (95% CI: 0.12–0.42, p<0.001) and menarche earlier by 0.17 years (95% CI: 0.05–0.29, p=0.005), with the effect on breast development 1.6 times larger than on menarche. Importantly, the effect was independent of BMI, confirming this is a direct genetic effect on neuroendocrine programming rather than an indirect effect through body composition.

The effect extends to pathological early puberty. Hu et al. (2016)⁷⁷ Hu et al. (2016)
Pediatric Research; 502 idiopathic central precocious puberty girls, 489 controls found CC homozygotes had an odds ratio of 0.527 for ICPP (95% CI: 0.329–0.843) compared to TT/TC carriers — i.e., having two protective C alleles reduces the risk of pathologically early puberty by approximately 47%. Cross-ethnic replication in 827 Filipino women (Croteau-Chonka et al., 2013)⁸⁸ 827 Filipino women (Croteau-Chonka et al., 2013)
Pediatric Obesity confirmed the T-allele direction (β=−0.118 years per allele, p=0.019), consistent with European data.

In males, the reproductive implications extend beyond puberty timing. Leinonen et al. (2019)⁹⁹ Leinonen et al. (2019)
Scientific Reports; UK Biobank, >350,000 individuals found the T allele at rs7759938 is robustly associated with higher serum testosterone in adult males (p=2.5×10⁻³⁷), while the C allele associates with lower testosterone. This suggests that LIN28B variants influence the HPG axis set-point throughout the reproductive lifespan, not only at puberty onset.

Downstream consequences of earlier menarche include a longer total estrogen exposure window, with associations documented for uterine leiomyoma (fibroid) risk. Ponomarenko et al. (2021)¹⁰¹⁰ Ponomarenko et al. (2021)
Frontiers in Genetics found rs7759938 was individually associated with uterine leiomyoma under the dominant model, the only SNP among 52 puberty-timing candidates to reach individual significance for fibroid risk.

Practical Implications

The key clinical interpretation is about reproductive window positioning rather than fertility impairment per se. Earlier menarche means an earlier start to cyclical ovulation — but it also means an earlier arrival at menopause if the total reproductive span is not extended proportionally. Epidemiological data generally support earlier menarche being associated with slightly earlier menopause as well, though this relationship is not driven by LIN28B variants directly.

For individuals with TT genotype considering family timing, the relevant insight is that earlier puberty may be associated with a slightly longer total reproductive window (more cycles before menopause) but also with greater cumulative estrogen exposure — which carries implications for uterine health and monitoring.

In clinical contexts involving precocious puberty evaluation, rs7759938 is among the genetic loci that can help distinguish [idiopathic/genetic early puberty from pathological causes | Central precocious puberty (CPP) requires GnRH stimulation testing and imaging; genetic variants shift the statistical distribution without being diagnostic individually].

For males with CT or TT genotype, the testosterone data suggest the LIN28B locus may contribute to HPG axis set-point at the population level, though individual variation is large and this does not have a direct clinical action at this time.

Interactions

rs314276 and rs314280 (LIN28B): These two additional LIN28B tag SNPs have independent but partially overlapping effects on puberty timing and adult height. rs7759938 and rs314277 had pairwise r²=0.29 in the Finnish cohort studied by Widén et al. (2010), meaning they tag partially distinct haplotype effects within the LIN28B locus. The combined haplotype effect on pubertal growth tempo is more informative than any single SNP alone.

rs11156429 (LIN28B region): The most significantly associated SNP for male voice breaking timing (GWAS p=3.5×10⁻⁵²) is also near LIN28B. The shared genetic architecture of puberty timing across sexes at this locus suggests a single quantitative regulatory mechanism that scales across male and female developmental milestones.

PCOS context: The LIN28B T allele effect on earlier menarche is preserved — and possibly amplified — in women with PCOS (Carroll et al., 2012: TT vs CC difference of 0.81 years in PCOS women vs ~0.6 years in controls). LIN28B variants may interact with PCOS-related hyperandrogenism to modify the timing of reproductive milestones. Supervisor note: a compound action for rs7759938 TT in the context of PCOS-associated SNPs (e.g. LHCGR, AMH pathway variants) should be considered if those are included in the fertility batch — the combined genotype may warrant earlier fertility assessment counseling.

IL1RL1¹¹ IL1RL1
Interleukin-1 receptor-like 1, also known as ST2 — a member of the interleukin-1 receptor family that acts as the receptor for the cytokine IL-33 occupies a pivotal position in type 2 immunity: it controls how vigorously the immune system responds to allergens, parasites, and airway insults. The gene on chromosome 2q12.1 produces two functionally distinct proteins. The membrane-anchored form, ST2L, sits on the surface of mast cells, innate lymphoid cells, and type 2 helper T cells, transmitting the IL-33 alarm signal that drives eosinophilic inflammation, IgE production, and airway hyperreactivity. The soluble form, sST2, acts as a decoy receptor — it circulates in the blood, binds free IL-33 with high affinity, and prevents it from ever reaching the membrane receptor, effectively dampening the type 2 inflammatory response.

The rs13408661 variant is an intronic G>A substitution that tags a haplotype block influencing sST2 levels. Individuals carrying the A allele have lower circulating sST2, which means their IL-33 decoy system has reduced capacity — more IL-33 remains free to activate mast cells, ILC2s, and eosinophils.

The Mechanism

IL1RL1 alternative splicing governs the ST2L/sST2 ratio. The full-length ST2L isoform contains all extracellular immunoglobulin-like domains plus a transmembrane helix and intracellular TIR signaling domain²² TIR signaling domain
Toll/interleukin-1 receptor domain — the conserved cytoplasmic region that recruits adaptor proteins (MyD88, IRAK4) to propagate the inflammatory signal. The sST2 isoform uses an alternative proximal promoter and lacks the transmembrane and TIR domains, so it is secreted rather than anchored to the cell surface.

Gordon et al. (2016)³³ Gordon et al. (2016)
JCI Insight 2016;1(14):e87871; UCSF and National Jewish Health; n=127–237 airway epithelial and lung parenchyma samples showed that GWAS risk alleles within the IL1RL1 locus operate through tissue-specific promoter elements: rs1420101 (a proxy for the rs13408661 haplotype) downregulates sST2 expression in airway epithelial cells via the proximal promoter, while rs11685480 operates in lung parenchyma via the distal promoter. In both tissues, the risk haplotype reduces the decoy receptor supply. Without adequate sST2 to sequester circulating IL-33, more IL-33 reaches ST2L on mast cells and ILC2s, sustaining type 2 cytokine production (IL-4, IL-5, IL-13) and eosinophil recruitment.

The Evidence

The association between this locus and asthma was first reported at genome-wide significance by the APCAT consortium⁴⁴ APCAT consortium
Ramasamy et al., PLoS One 2012;7(9):e44008; six European-descent population-based cohorts, 1,716 asthma cases and 16,888 controls. The consortium identified rs13408661 near IL1RL1/IL18R1 with P=1.1×10⁻⁹, correlated with the previously reported rs3771180, confirming the locus in an independent European dataset. The IL1RL1 locus association was subsequently replicated across European, African, and Latino ancestries in the CAAPA meta-analysis⁵⁵ CAAPA meta-analysis
Torgerson et al., Nature Genetics 2011;43:887–892; 5,416 asthma cases, replication in 12,649 individuals, establishing it as one of the most robustly replicated asthma susceptibility loci.

The functional link between the rs13408661 A-allele haplotype and sST2 biology is confirmed by the Teräsjärvi 2024 birth cohort study, which found that rs13408661 variant carriers had substantially lower serum sST2 concentrations⁶⁶ substantially lower serum sST2 concentrations
p<0.0001; AC/AA genotype group median sST2 ~2,453 pg/mL versus CC carriers ~5,437 pg/mL at the linked rs1041973 locus, and children with these variants showed a trend toward higher asthma incidence, though the sample (146 Finnish children) was underpowered to reach statistical significance on its own. The Riikonen et al. 2022 study⁷⁷ Riikonen et al. 2022 study
Acta Paediatrica 2022;111(3):628–635; n=125–141 children followed to age 5–7 and 11–13 years after infant bronchiolitis hospitalization found the rs13408661 variant genotype consistently associated with persistent post-bronchiolitis asthma across multiple definitions at both follow-up time points, though the association attenuated when maternal asthma and early atopic dermatitis were controlled for — suggesting that the genetic effect may operate partly through shared familial pathways.

The functional translation of the locus is further supported by the Gordon et al. finding that carriers of 3–4 IL1RL1 risk alleles (spanning the rs13408661 haplotype region) had 2.85-fold increased odds of type 2 airway inflammation⁸⁸ 2.85-fold increased odds of type 2 airway inflammation — the eosinophilic, high-FeNO, steroid-responsive endotype that is clinically tractable. The locus effect appears particularly relevant for this type 2-high phenotype rather than neutrophilic or mixed asthma.

Practical Actions

Individuals carrying the A allele — particularly GA heterozygotes who represent roughly 29% of the global population and AA homozygotes (~3%) — have a sST2 system that is somewhat less effective at buffering IL-33 surges. In practical terms, this means the type 2 inflammatory signaling cascade (mast cell degranulation, IgE production, eosinophil recruitment) may be easier to trigger and harder to switch off after allergen or respiratory virus exposure.

The most directly actionable implication is to minimize IL-33-triggering exposures: allergen load reduction, viral respiratory illness prevention (which is a potent IL-33 trigger in the airway epithelium), and monitoring lung function during respiratory infections. For individuals with diagnosed asthma or allergic rhinitis who carry the A allele, the type 2-high phenotype (elevated blood or sputum eosinophils, elevated FeNO) is more likely, which has implications for which controller therapies are likely to be effective.

Interactions

rs13408661 sits on chromosome 2q12.1 within a broader IL1RL1/IL18R1/IL18RAP gene cluster. The locus contains at least four independent association signals for asthma and related traits (as characterized by Portelli et al. 2020, PMID 32324168), of which rs13408661 tags a haplotype overlapping with the major Signal A (rs995514 proxy for rs12474258). Other SNPs in the same haplotype block — particularly rs1420101, rs11685480, rs1041973, and rs1921622 — regulate sST2 expression through different promoters and in different tissues, and their effects are partially independent.

The biologically paired variant on chromosome 9p24.1 is IL-33 itself (rs146597587 in IL33), the ligand for ST2. Individuals who carry both an IL1RL1 A-allele (reduced sST2 decoy) and an IL33 high-expression variant would be expected to have compounded type 2 inflammatory drive — more IL-33 produced and less decoy to neutralize it — though this specific combination has not been directly studied in a single cohort.